[go: up one dir, main page]

RU2007115093A - Производное циклического амина или его соль - Google Patents

Производное циклического амина или его соль Download PDF

Info

Publication number
RU2007115093A
RU2007115093A RU2007115093/04A RU2007115093A RU2007115093A RU 2007115093 A RU2007115093 A RU 2007115093A RU 2007115093/04 A RU2007115093/04 A RU 2007115093/04A RU 2007115093 A RU2007115093 A RU 2007115093A RU 2007115093 A RU2007115093 A RU 2007115093A
Authority
RU
Russia
Prior art keywords
lower alkyl
dimethyl
indan
lower alkylene
methylpiperidin
Prior art date
Application number
RU2007115093/04A
Other languages
English (en)
Other versions
RU2347776C2 (ru
Inventor
Сатоси ХАЯСИБЕ (JP)
Сатоси ХАЯСИБЕ
Такатоси КАНАЯМА (JP)
Такатоси КАНАЯМА
Дзуниа ОХМОРИ (JP)
Дзуниа Охмори
Такахико ТОБЕ (JP)
Такахико ТОБЕ
Киоити МАЕНО (JP)
Киоити МАЕНО
Йосицугу СИТАКА (JP)
Йосицугу СИТАКА
Дзотароу СУЗУКИ (JP)
Дзотароу СУЗУКИ
Сигеки КАВАБАТА (JP)
Сигеки КАВАБАТА
Нобуюки СИРАИСИ (JP)
Нобуюки СИРАИСИ
Синго ЯМАСАКИ (JP)
Синго ЯМАСАКИ
Даисуке СУЗУКИ (JP)
Даисуке СУЗУКИ
Хироаки ХОСИЙ (JP)
Хироаки ХОСИЙ
Original Assignee
Астеллас Фарма Инк. (Jp)
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. (Jp), Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк. (Jp)
Publication of RU2007115093A publication Critical patent/RU2007115093A/ru
Application granted granted Critical
Publication of RU2347776C2 publication Critical patent/RU2347776C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (9)

1. Циклический амин или его соль следующей формулы (I):
Figure 00000001
где A - 5-8-членный циклический амин, необязательно содержащий двойную связь, необязательно имеющий мостиковую структуру и необязательно содержащий заместители R7-R11 в кольце, или -NH2, -NH(низший алкил) или -N(низший алкил)2;
кольцо B - бензол, тиофен, фуран, пиррол, 5-7-членный циклоалкан или 5-7-членный циклоалкен;
X1 - связь, низший алкилен или -L3-D-L4-;
L3 и L4 - одинаковые или различные, каждый представляет собой связь или низший алкилен;
D - 5- или 6-членный карбоцикл или 5- или 6-членный гетероцикл, необязательно содержащий заместитель;
X2 - -(CR12R13)n-, -N(R14)-, -N(R14)CO-, -CON(R14)-, -CO-, -CH(OH)-, -N(R14)-(CR12R13)n-, -(CR12R13)n-N(R14)-, -CON(R14)-(CR12R13)n-, -N(R14)CO-(CR12R13)n-, -(CR12R13)n-N(R14)CO-, -(CR12R13)n-CON(R14)-, -CO-(CR12R13)n- или -(CR12R13)n-CO-;
Y1 - -OH, -O-низший алкил, -NH2 или -N3;
R1 и R2 - одинаковые или различные и представляют собой атом галогена, низший алкил или низший алкилен-OH;
R3-R6 - одинаковые или различные и представляют собой атом водорода, атом галогена, низший алкил, низший алкенил, низший алкинил, -O-низший алкил, -OH, -NH2, -NH(низший алкил), -N(низший алкил)2, -NH-CO-низший алкил, -N(низший алкил)-CO-низший алкил, -NH-CO-O-низший алкил, -N(низший алкил)-CO-O-низший алкил, -CN-, -NO2, -CF3, -низший алкилен-OH, -низший алкилен-атом галогена, -O-низший алкилен-OH, -низший алкилен-O-низший алкил, -CO-N(низший алкил)2, -CO-NH-(низший алкил), -O-CO-N(низший алкил)2, -O-CO-NH-(низший алкил), 5-8-членный циклический амин, -CO-5-8-членный циклический амин, -COOH, -COO-низший алкил, -COO-низший алкилен-арил, 5- или 6-членный гетероцикл, -низший алкилен-, 5- или 6-членный гетероцикл, арил, необязательно содержащий заместитель, или арил, необязательно содержащий -низший алкилен-заместитель;
R7 - атом водорода, низший алкил, -низший алкилен-арил или -низший алкилен-гетероарил:
R7 представляет собой заместитель на атоме азота циклического амина;
R8-R14 - одинаковые или различные и представляют собой атом водорода или низший алкил;
n - целое число 1, 2 или 3;
где R5 и R6, R4 и R5 или R3 и R4 могут вместе образовывать низший алкилен, -O-низший алкилен-O-, -O-низший алкилен-, -низший алкилен-O-, -S-низший алкилен-, -низший алкилен-S-, -N(R19)-низший алкилен-, -низший алкилен-N(R19)-, -C(R15)=C(R16)-O-, -O-C(R15)=C(R16)-, -C(R15)=C(R16)-C(R17)=C(R18)-, -S-C(R15)=C(R16)-, -C(R15)=C(R16)-S-, -N(R19)-C(R15)=C(R16)-, -C(R15)=C(R16)-N(R19)-, -N(R19)-C(R15)=N-, -N=C(R15)-N(R19)-, -N=C(R15)-C(R16)=C(R17)-, -C(R15)=C(R16)-C(R17)=N-, -C(R15)=N-C(R16)=C(R17)- или -C(R15)=C(R16)-N=C(R17)-;
R3 и Y1 могут вместе образовывать -O-низший алкилен-O-, -низший алкилен-O- или -N(R19)-низший алкилен-O-;
R1 и Y1 могут вместе образовывать -низший алкилен-O-;
Y1 и ответвление на -X1-A могут вместе образовывать -O- или -O-низший алкилен;
R15-R18 - одинаковые или различные и представляют собой атом водорода, атом галогена или низшую алкильную группу;
R19 - атом водорода или низшая алкильная группа;
при условии, что 6-хлор-2,2-диметил-1-(1-метил-4-пиперидинил)индан-1-ол исключен из группы соединений).
2. Производное циклического амина или его соль следующей формулы (II):
Figure 00000002
где кольцо А - 5-7-членный циклический амин, необязательно содержащий двойную связь в кольце;
кольцо B - бензол, тиофен, фуран, пиррол, 5-7-членный циклоалкан или 5-7-членный циклоалкен;
X1 - связь или низший алкилен;
X2 - -(CR12R13)n-, -N(R14)-, -N(R14)CO-, -CON(R14)-, -CO-, -N(R14)-(CR12R13)n-, -(CR12R13)n-N(R14)-, -CON(R14)-(CR12R13)n-, -N(R14)CO-(CR12R13)n-, -(CR12R13)n-N(R14)CO-, -(CR12R13)n-CON(R14)-, -CO-(CR12R13)n- или -(CR12R13)n-CO-;
Y1 - -OH, -O-низший алкил, -NH2 или -N3;
R1 и R2 - одинаковые или различные и представляют собой атом галогена или низший алкил;
R3-R6 - одинаковые или различные и представляют собой атом водорода, атом галогена, низший алкил, -O-низший алкил, -OH, -CN или -CF3;
R7 - атом водорода, низший алкил, -низший алкилен-арил или -низший алкилен-гетероарил:
R8-R14 - одинаковые или различные и представляют собой атом водорода или низший алкил;
n - целое число 1, 2 или 3;
при условии, что 6-хлор-2,2-диметил-1-(1-метил-4-пиперидинил)индан-1-ол исключен из группы соединений).
3. Циклический амин или его соль следующей формулы (III):
Figure 00000003
где X1 - связь или низший алкилен;
Y1 - -OH, -O-низший алкил, -NH2 или -N3;
R1 и R2 - одинаковые или различные и представляют собой атом галогена или низший алкил;
R3-R6 - одинаковые или различные и представляют собой атом водорода, атом галогена, низший алкил, -O-низший алкил, -OH, -CN или -CF3;
R7 - атом водорода, низший алкил, -низший алкилен-арил или -низший алкилен-гетероарил ;
R8-R11 - одинаковые или различные и представляют собой атом водорода или низший алкил;
R8-R11 - одинаковые или различные и представляют собой атом водорода или низший алкил;
при условии, что 6-хлор-2,2-диметил-1-(1-метил-4-пиперидинил)индан-1-ол исключен из группы соединений).
4. Соединение или его соль по п.1, выбранное из 2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 2,2,6-триметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 6-фтор-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 5-бром-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 6-хлор-5-фтор-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 6-бром-4-фтор-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 7-бром-6-фтор-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 7-бром-4-фтор-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 6-фтор-7-метокси-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 4-фтор-7-метокси-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 2,2-диметил-1-(1-метилпиперидин-4-ил)-1,2,3,4-тетрагидронафталин-1-ола, 4-фтор-6-метокси-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 7-этокси-6-фтор-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 4-фтор-6,7-диметокси-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 5,6-дифтор-7-метокси-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 6-циано-4-фтор-7-метокси-2,2-диметил-1-(1-метилпиперидин-4-ил)индан-1-ола, 1-(2-амино-2-метилпропил)-2,2,6-триметилиндан-1-ола, 5-фтор-7,7-диметил-8-(1-метилпиперидин-4-ил)-3,6,7,8-тетрагидро-2H-индено[4,5-b]фуран-8-ола, 4-(9-фтор-5,5-диметил-2,3,5,6-тетрагидро-4aH-индено[1,7-ef][1,4]диоксепин-4a-ил-1-метилпиперидина, 1-[(6'-фтор-7'-метокси-2',2'-диметил-2',3',4,5-тетрагидро-3H-спиро[фуран-2,1'-инден]-5-ил)метил]пирролидина, 7-бром-2,2-диметил-(1-метилпиперидин-4-ил)индан-1-ола.
5. Фармацевтическая композиция, содержащая производное циклического амина или его соль по п.1.
6. Фармацевтическая композиция по п.5, которая является антагонистом рецептора NMDA.
7. Фармацевтическая композиция по п.5, которая является средством для лечения деменции.
8. Применение циклического амина или его соли по п.1 для получения антагониста рецептора NMDA или средства для лечения деменции.
9. Способ лечения деменции, включающий введение пациенту терапевтически эффективного количества производного циклического амина или его соли по п.1.
RU2007115093/04A 2004-09-21 2005-09-20 Производное циклического амина или его соль RU2347776C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-274105 2004-09-21
JP2004274105 2004-09-21

Publications (2)

Publication Number Publication Date
RU2007115093A true RU2007115093A (ru) 2008-11-10
RU2347776C2 RU2347776C2 (ru) 2009-02-27

Family

ID=36090077

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007115093/04A RU2347776C2 (ru) 2004-09-21 2005-09-20 Производное циклического амина или его соль

Country Status (15)

Country Link
US (1) US20070197594A1 (ru)
EP (1) EP1795524A4 (ru)
JP (1) JP4748320B2 (ru)
KR (1) KR20070064437A (ru)
CN (1) CN101023055B (ru)
AU (1) AU2005285878B2 (ru)
BR (1) BRPI0515525A (ru)
CA (1) CA2580980C (ru)
IL (1) IL181897A (ru)
MX (1) MX2007003337A (ru)
NO (1) NO20072036L (ru)
RU (1) RU2347776C2 (ru)
TW (1) TW200621677A (ru)
WO (1) WO2006033318A1 (ru)
ZA (1) ZA200702333B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010481A1 (en) * 2006-07-18 2008-01-24 Astellas Pharma Inc. Aminoindan derivative or salt thereof
WO2008064342A2 (en) * 2006-11-21 2008-05-29 Omeros Corporation Pde10 inhibitors and related compositions and methods
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
HRP20120944T1 (hr) 2007-11-28 2012-12-31 Astellas Pharma Inc. Kondenzirani spoj indana
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
CN105481864A (zh) 2009-05-22 2016-04-13 Abbvie公司 5-ht受体的调节剂及其使用方法
CA2788656A1 (en) 2010-02-16 2011-08-25 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
WO2011146089A1 (en) 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
AR092924A1 (es) 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
US20220257532A1 (en) * 2017-06-16 2022-08-18 Korpharm Co., Ltd. Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases
KR102085358B1 (ko) * 2017-06-21 2020-03-05 고려대학교 산학협력단 프테로신 화합물 및 이의 유도체를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
WO2019189781A1 (ja) 2018-03-30 2019-10-03 東レ株式会社 神経細胞内カルシウム濃度上昇抑制剤
CN110357339B (zh) * 2019-08-14 2021-08-31 盛隆资源再生（无锡）有限公司 一种利用高氟高氨氮废水连续生产氟化钠的方法
IT201900017330A1 (it) * 2019-09-26 2021-03-26 Isagro Spa Processo per la preparazione di (r)-4-amminoindani e corrispondenti ammidi.
AU2021343668A1 (en) * 2020-09-15 2023-04-13 Teijin Pharma Limited Vitamin D derivative having cyclic amine in side chain
WO2026015507A1 (en) * 2024-07-08 2026-01-15 Otsuka America Pharmaceutical, Inc. Compounds useful for the treatment of disorders and methods related thereto

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470055A1 (de) * 1963-12-07 1969-07-17 Merck Ag E Verfahren zur Herstellung von Piperidinderivaten
CH647235A5 (de) * 1980-02-13 1985-01-15 Sandoz Ag 4-(2,2-dialkylindan-1-yliden)piperidin derivate, ihre herstellung und verwendung.
IE55972B1 (en) * 1982-10-07 1991-03-13 Kefalas As Phenylindene derivatives,acid addition salts thereof,and methods of preparation
EP0392059B1 (de) * 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
US5703239A (en) * 1995-06-02 1997-12-30 Bristol-Myers Squibb Company Indanylpiperidines as melatonergic agents
CA2220649C (en) * 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
HU226110B1 (en) * 1997-06-30 2008-04-28 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane nmda receptor antagonists, pharmaceutical compositions containing and their use
NZ516782A (en) * 1999-07-28 2004-12-24 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
DE10050236A1 (de) * 2000-10-11 2002-04-25 Merck Patent Gmbh Verwendung bestimmter Substanzen, die an den Sigma-Rezeptor binden, zur Behandlung von Sarkomen und Karzinomen
JP4357802B2 (ja) * 2001-07-05 2009-11-04 武田薬品工業株式会社 ベンゼン環縮合５員複素環式化合物、その製造法および用途
EP1411052B1 (en) * 2001-07-05 2011-10-05 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof

Also Published As

Publication number Publication date
BRPI0515525A (pt) 2008-08-05
IL181897A (en) 2012-05-31
EP1795524A1 (en) 2007-06-13
EP1795524A4 (en) 2009-08-05
AU2005285878A1 (en) 2006-03-30
WO2006033318A1 (ja) 2006-03-30
MX2007003337A (es) 2007-05-21
US20070197594A1 (en) 2007-08-23
TW200621677A (en) 2006-07-01
KR20070064437A (ko) 2007-06-20
CN101023055B (zh) 2010-10-06
CN101023055A (zh) 2007-08-22
TWI337988B (ru) 2011-03-01
IL181897A0 (en) 2007-07-04
CA2580980A1 (en) 2006-03-30
NO20072036L (no) 2007-05-23
AU2005285878B2 (en) 2011-06-30
ZA200702333B (en) 2009-05-27
JPWO2006033318A1 (ja) 2008-05-15
RU2347776C2 (ru) 2009-02-27
JP4748320B2 (ja) 2011-08-17
CA2580980C (en) 2011-05-03

Similar Documents

Publication Publication Date Title
RU2007115093A (ru) Производное циклического амина или его соль
RU2003132687A (ru) Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
RU2221795C2 (ru) Имидазолил-циклические ацетали, промежуточные соединения, фармацевтическая композиция и способ лечения
RU2489148C2 (ru) Ингибитор активации stat3/5
RU2008146088A (ru) Оксадиазолидиндионовое соединение
CA2494613A1 (en) Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
AR033306A1 (es) Compuestos
RU2004115737A (ru) Соединение хинолина
RU2008140144A (ru) Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента
RU2226527C2 (ru) Производные 2-аминопиридинов, фармацевтические композиции на их основе и промежуточные вещества
RU2005136368A (ru) Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний
CA2526145A1 (en) C-glycoside derivatives or salts thereof for use as na+-glucose cotransporter inhibitors
AR036115A1 (es) Compuesto de n-aroilaminas, composiciones farmaceuticas formuladas con dichos compuestos; uso de los compuestos mencionados en la preparacion de composiciones farmaceuticas para tratar,prevenir enfermedades o trastornos donde se requiere la aplicacion de antagonistas de receptores de la orexina huma
AR035979A1 (es) Derivados de quinolina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden, y usos de dichos compuestos para la preparacion de medicament0s
RU2009117469A (ru) Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
RU2008126228A (ru) 2-аминобензамидное производное
AR036939A1 (es) Antagonistas de la hormona de concentracion de melanina (mch) composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o en combinacion, para la elaboracion de un medicamento para el tratamiento de obesidad
RU2003136097A (ru) Производные фенилпиридинкарбонилпиперазина
ATE235476T1 (de) Thiazolidindione derivate, ihre herstellung und verwendung
RU2007106969A (ru) Новые пиперидиновые производные в качестве лигандов гистаминового рецептора для лечения депрессии
DE69402981D1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazine als 5ht1a ligande
JP2017520530A5 (ru)
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
BR0111976A (pt) Preparação terapêutica para neurose ou depressão por ansiedade, e, derivado de piperazina
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130921